09 Jul 2019
Posted in Pharma
B-cell non-Hodgkin’s lymphoma diagnosed incident cases set to reach 183,000 in 2027
The burden of diagnosed B-cell non-Hodgkin’s lymphoma (NHL) is expected to increase at an annual growth rate (AGR) of 1.87% from around 154,000 cases in 2017 to 183,000 cases in 2027 in the seven major markets (7MM*), according to GlobalData, a leading data and analytics company.
GlobalData’s latest report: ‘B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2027’ reveals that the increase is partly attributed to the moderately rising trend in incidence in the 7MM, combined with underlying demographic changes in the respective markets.
In the 7MM, diffuse large B-cell lymphoma (DLBCL) was the most common subtype of B-cell NHL, followed by follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
Bishal Bhandari, Epidemiologist at GlobalData, comments: “GlobalData’s research shows that DLBCL is the most common subtype of B-cell NHL. This is important as it is the more aggressive form of cancer with poor prognosis and the risk of mortality from DLBCL will increase in the elderly population with other co-existing diseases and conditions; making it an important patient population to focus on.”
In the 7MM, according to GlobalData, the majority of diagnosed incident cases of DLBCL were in stage IV and the fewest were in stage III in 2017.
Bhandari concludes: “It is worrying that most cases of DLBCL were diagnosed in the advanced stages as survival will be poor and patients would have required aggressive therapy to get the cancer under control.
“There is a need for diagnostic tools to detect aggressive cancer such as DLBCL at earlier stages and treatment priorities should also be aligned to address the aggressive form of cancer.”
*7MM: The US, France, Germany, Italy, Spain, the UK and Japan